Abstract
Fundamental and clinical studies of ofloxacin (OFLX), a new oral quinolon antibiotic, were carried out on oral infections of 60 patients. The concentration of OFLX in the gingiva and serum was determined 3 hours after it was administered orally (100mg). In addition, the clinical efficacy of OFLX was evaluated and bacterial sensitivity tests in patients with oral maxillofacial infection were carried out. OFLX was administered orally at a dose of 600 mg for three days to eight days.
1) Gingiva and serum concentrations of OFLX (100mg administered) were 0.82±0.4μg/g and 1.02±0.5μg/ml, respectively. In 91%(21) of the bacterial strains isolated the MIC was less than 1.56μg/ml, which means the sensitivity to OFLX was quite favorable.
2) OFLX (100mg), lomefloxacin (100mg) and tosufloxacin (150mg) were administered orally at the same time 3 hours before surgery. The tissue and serum concentrations of OFLX were 0.74±0.4μg (gingiva), 0.99±0.5μg/ml (serum), which was higher than those of lomefloxacin and tosufloxacin.
3) The clinical response to OFLX was excellent in 2 cases, good in 17 cases, fair in no cases and poor in 1 case. Thus the clinical efficacy was 95% overall. The efficacy rate on day 3 (n=13) was 76.9%; on day 5 (n=5), 80%, and there were no safety problems.
It was concluded that OFLX is a useful drug for treating oro-maxillofacial infections.
